Nasal Administration of Novel Recombinant Protozoan Strain Prevents Metastatic Melanoma in the Lung
Source: Pharmacy Times, May 2023
The protozoan intranasal treatment was associated with a strong increase of immune cells within the lung.
When administered via mucosal administration, human interleukin-15 (IL-15) and IL receptor alpha (IL-15R?)-secreting protozoan Neospora caninum (N. caninum) fused to the sushi domain of IL-15 receptor (NC1-IL-15hRec) could be a non-invasive, effective, and safe immunotherapeutic approach for metastatic melanoma, according to the results of a recent study published in BMJ.
IL-15 is more stable when bound to the high affinity receptor IL-15R?. Once genetically engineered to the N. caninum protozoan, this novel strain improves T cell survival and activation, enhancing the effector responses of natural killer (NK) cells that target tumors and cluster of differentiation 8 (CD8+) cells.